•A
novel immuno
modulatory agent developed, exploiting highly selective affinity of a small
homing peptide 'CSG' for tumour
ECM.
•TNF-CSG
stimulates local activation of native immune cells, leading to tumour
ECM degradation, significantly reduced tumour
stiffness and interstitial pressure, and increased tumour
perfusion.
•Used
as an adjunct therapy TNF-CSG has the potential to increase efficacy and reduce
toxicity of chemo and immunotherapy drugs (and to enhance tumour
detection by imaging agents).
In
addition
TNF-CSG has direct anti cancer activity as a monotherapy
